ADMA Biologics (ADMA) Prices 23.5M Share Upsized Common Offering at $3.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
ADMA Biologics (ADMA) Announces Proposed $75M Share Common Offering
February 7, 2020 6:09 AM ESTADMA Biologics, Inc. (NASDAQ: ADMA) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced that it has commenced an $75 million underwritten public offering of... More
After-Hours Stock Movers 02/06: (ASRT) (PINS) (UBER) Higher; (ZGNX) (MYGN) (RESN) Lower (more...)
February 6, 2020 6:01 PM ESTAfter-Hours Stock Movers
Assertio Therapeutics, Inc. (NASDAQ: ASRT) 51% HIGHER; entered into a definitive agreement (Agreement) with Collegium Pharmaceutical, Inc. (Nasdaq: COLL) pursuant to which Collegium will acquire the NUCYNTA® franchise of products from the Company. The closing of the agreement is expected by February 14, 2020.
Zogenix, Inc. (NASDAQ: ZGNX) 33% LOWER; reported positive top-line results from its global Phase 3 clinical trial (Study 1601) of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution) in... More
ADMA Biologics (ADMA) to Offer $75M in Stock
February 6, 2020 4:09 PM ESTADMA Biologics, Inc. (Nasdaq: ADMA) announced that it has commenced an $75 million underwritten public offering of its common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of... More
